Related Experiment Video

Updated: Jun 23, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized

E Mannucci1, M Monami, C Lamanna

  • 1Section of Geriatric Cardiology, Department of Cardiovascular Medicine, Azienda Ospedaliero-Universitaria Careggi, Via delle Oblate 4, 50141 Florence, Italy. edoardo.mannucci@unifi.it

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
|May 12, 2009
PubMed
Abstract

Insights

Intensified blood glucose control in type 2 diabetes significantly reduces heart attacks but not strokes or cardiovascular deaths. Severe hypoglycemia may increase cardiovascular mortality risk.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Previous randomized clinical trials (RCTs) on lowering blood glucose for diabetic complications have not shown significant cardiovascular event reduction.
  • Glycemic control is crucial for managing type 2 diabetes and its associated risks.

Purpose of the Study:

  • To assess the impact of improved glycemic control on cardiovascular disease incidence in type 2 diabetes patients.
  • To analyze data from RCTs with specific criteria for glycemic control and cardiovascular endpoints.

Main Methods:

  • Meta-analysis of five RCTs involving over 32,000 patients.
  • Inclusion criteria: ≥0.5% HbA1c difference, ≥3 years duration, cardiovascular endpoint.
  • Independent data extraction and senior investigator review.

Main Results:

  • Intensive glycemic control (average 0.9% HbA1c reduction) significantly lowered myocardial infarction (OR 0.86) and overall cardiovascular events (OR 0.89).
  • No significant effect was observed on stroke incidence or cardiovascular mortality.
  • Higher BMI, longer diabetes duration, and severe hypoglycemia were linked to increased cardiovascular death risk in intensive treatment groups.

Conclusions:

  • Intensified glycemic control in type 2 diabetes effectively reduces myocardial infarction incidence.
  • Stroke and cardiovascular mortality rates were not significantly affected by intensified treatment.
  • Severe hypoglycemia associated with intensified treatment may increase cardiovascular mortality risk.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...